NCT04697511View on ClinicalTrials.gov

Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

February 25, 2021

Study Completion Date

February 25, 2021

Conditions
Healthy
Interventions
DRUG

Midazolam

Participants will receive single oral dose of midazolam on Days 1, 3 and 13 under fed conditions.

DRUG

M2951

Participants will receive multiple oral doses (twice daily) of M2951 on Day 3 to Day 13 under fed conditions.

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT04697511 - Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy Participants | Biotech Hunter | Biotech Hunter